Explore

Trendline Trendline
Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors
Trendline Trendline
enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial

enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial

enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial
Trendline Trendline
Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome

Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome

Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome
Trendline Trendline
Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone
Trendline Trendline
FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease

FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease

FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease
Trendline Trendline
Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment
Trendline Trendline
Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment
Trendline Trendline
Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission
Trendline Trendline
Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy
Trendline Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing

Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing

Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing